Sudhir Gupta
Cardiovascular Disease · Shawnee, OKNPI 1437119286
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $552 of the $668 with a category attached, or 82.6%. 11 manufacturers reported payments, led by Boston Scientific at 33.9% of the total. Reporting peaked in 2022 at $334 and has fallen 84.2% since, to $53 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in OK, where the typical reported total is $2,806.
Across 17 payments — averaging $39.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$227
- Biotronik Inc.$148
- Novo Nordisk$116
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$31
- Abbott$28
- Amgen$26
- plus $91 from 5 others
Across 1 payment — averaging $32,445 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shire North American Group Inc$32K
What the payments were for
- Food & beverage$55283%
- Education$11617%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 6 | $227 |
| Biotronik Inc. | 1 | $148 |
| Novo Nordisk | 1 | $116 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $31 |
| Abbott | 1 | $28 |
| Amgen | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Lantheus Medical Imaging, Inc. | 1 | $19 |
| Edwards Lifesciences | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Acticor 7 VR-T DX$148
- Ozempic$116
How this compares
$668 in reported general payments places this provider in the 25th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 489 | $497,083 |
| EntrestoSacubitril/Valsartan | 247 | $289,544 |
| XareltoRivaroxaban | 114 | $119,700 |
| JardianceEmpagliflozin | 49 | $60,132 |
| Repatha SureclickEvolocumab | 22 | $24,664 |
| Losartan Potassium | 639 | $9,062 |
| BrilintaTicagrelor | 16 | $9,053 |
| Atorvastatin Calcium | 721 | $8,571 |
| FarxigaDapagliflozin Propanediol | 11 | $8,337 |
| Metoprolol Succinate | 474 | $7,890 |
| Repatha SyringeEvolocumab | 14 | $7,885 |
| Ranolazine ErRanolazine | 60 | $5,649 |
| Carvedilol | 594 | $5,219 |
| Ezetimibe | 161 | $5,022 |
| Digoxin | 145 | $4,023 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $497,083489 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Shawnee
- Frank GaffneyTulsa$211K
- Anderson MehrleBartlesville$129K
- Aly El BanayosyOklahoma City$54K
- Dwight ReynoldsOklahoma City$47K
- Mohamad KhattabTulsa$47K
- Udho ThadaniOklahoma City$41K
- Steve KimTulsa$38K
- Robert SullivanOklahoma City$36K
- Eric AuerbachTulsa$35K
- Reji PappyOklahoma City$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.